Table 2.

Dosimetric data for PTV, uPRV and OAR with and without ERB. Comparison between the treatment plans Vm_ref and Vm₄

	ERB			No ERB
	Vmref	Vm4	P-value	Vmref	Vm4	P-value
PTV
HI (u.a.)	0.096 [0.071–0.119]	0.099 [0.082–0.121]	0.721	0.086 [0.066–0.102]	0.096 [0.076–0.105]	0.156
DSC (u.a.)	0.779 [0.714–0.898]	0.773 [0.689–0.906]	1	0.810 [0.738–0.948]	0.795 [0.698–0.89]	1
D2% (Gy)	38.0 [37–38.9]	38.1 [37.4–39]	0.433	37.6 [36.8–38.2]	38.0 [37.2–38.3]	0.276
uPRV
HI (u.a.)	0.088 [0.051–0.13]	0.092 [0.06–0.121]	1	0.099 [0.057–0.139]	0.098 [0.063–0.199]	1
Rwall
D10% (Gy)	32.6 [29.9–35.8]	32.4 [25.6–35.7]	0.229	31.8 [29.9–35.6]	30.9 [26.7–35.3]	0.172
D20% (Gy)	23.1 [18.2–28.8]	19.8 [10.7–27.6]	<  0.001	24.7 [19.2–29.5]	19.2 [14.4–28.5]	<  0.001
D30% (Gy)	17.9 [15–22.9]	8.5 [6.2–13.1]	<  0.001	19.6 [14.5–24.9]	8.3 [6.1–13.7]	<  0.001
D40% (Gy)	15.2 [13–20.8]	6.5 [5.5–7.3]	<  0.001	16.6 [12.5–23.5]	6.0 [5.1–7.3]	<  0.001
D50% (Gy)	12.9 [4.2–19.6]	6.0 [3.3–6.8]	<  0.001	12.8 [6.3–22.2]	5.0 [4.1–6.5]	<  0.001
D60% (Gy)	9.1 [2.5–18.2]	5.4 [2.2–6.4]	<  0.001	6.1 [2.4–19.7]	4.1 [2.2–5.8]	0.041
Dmed (Gy)	12.9 [4.1–19.5]	5.9 [3.3–6.7]	<  0.001	12.2 [6.3–22.1]	4.9 [4–6.5]	<  0.001
Bwall
V18.1 Gy (%)	32.6 [15.6–47.5]	28.5 [13.3–45.5]	0.010	26.0 [14.9–44.8]	23.2 [13.1–41.8]	0.036
Fheads
D2%	10.6 [9–14.1]	16.3 [13.7–17.8]	<  0.001	11 [8.3–12.6]	13.3 [10.7–16.5]	0.141
MU	2110 [1788–2478]	2897 [2515–3168]	<  0.001	2256 [1834–2897]	2763 [2419–3161]	0.002